Paves way for rapid commercial expansion in hospital emergency departments of the first and only
Brain-assessment device innovator BrainScope, and
'More than four million patients seek care each year at hospital emergency departments for mild traumatic brain injuries. BrainScope is the only FDA-cleared technology that can objectively assess both brain bleeds and concussions in minutes and bring the needed diagnostic insights to help steer these patients to appropriate care,' said
BrainScope's proprietary system consists of disposable headsets that connect to its handheld device, which acquires, processes, and extracts thousands of brain activity-based physiological parameters characterizing the EEG signal, transforming them into an actionable result through artificial intelligence derived algorithms. The non-invasive, true point-of-care BrainScope assessment takes less than 20 minutes from patient prep to results enabling doctors to get rapid, objective insights about the likelihood of brain bleeds and concussions. In concussion management, the Concussion Index is the first physiological marker of concussive injury that aids clinicians in the objective assessment of patients at time of injury, and which can be reliably used to interpret change overtime.
'Innovation is the key to a growth economy, but intangible assets are the foundation. That is why we are bringing unique solutions to the market to help growth stage companies like BrainScope maximize the value of their intellectual property,' said
Aon is bringing solutions to the market that help companies avoid capital raises that can result in dilution of equity value. Aon's Intellectual Property (IP) Solutions team combined its proprietary IP valuation tools and a collateral protection insurance policy to help create an IP-collateralized debt structure that allowed BrainScope to raise additional funds without diluting the current equity value. IP and intangible assets now represent 90 percent of the value of Fortune 500 companies, but IP value is not widely understood in capital markets. Aon is working with companies like BrainScope to help them seek access to non-dilutive growth capital by valuing intangible assets and structuring capital solutions that leverage such value.
About BrainScope
BrainScope is a medical neurotechnology company that is improving brain health by providing objective, diagnostic insights that enable better patient care. BrainScope is leading the way in the rapid and objective assessment of brain-related conditions, starting with mild traumatic brain injury (mTBI), utilizing multiple integrated assessment capabilities, artificial intelligence (AI), and digitization. The company's technology supports the
About Aon
Follow Aon on Twitter and LinkedIn. Stay up-to-date by visiting the Aon Newsroom and sign up for News Alerts here.
Media Contacts:
VP, Brand Experience
cherie.lucier@brainscope.com
+1 215.805.0131
Global Media Relations
mediainquiries@aon.com
+1 833.751.8114
(C) 2021 Electronic News Publishing, source